TWSTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Twist Bioscience Corp
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$139.77+7.02 (+5.29%)
Close on Oct 19, 2026
- Market cap
- $8.72B
- P/E (TTM)
- –
- Dividend yield
- –
Twist Bioscience Corp revenue by segment
By business segment
By product or service
| Revenue | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NGS applications | $224.92M | $218.40M | $212.10M | $208.10M | $200.61M | $188.73M | $178.35M | $169.13M | $160.70M | $150.54M | $138.76M | $123.71M | 52.1% | +12.1% |
| DNA synthesis and protein solutions | $167.35M | $151.55M | $139.92M | $23.45M | $127.79M | $92.12M | $55.17M | $20.33M | $18.42M | $17.89M | $20.23M | $23.17M | 38.8% | +31.0% |
| Synthetic genes | – | – | – | $113.60M | $108.04M | $105.30M | $99.44M | $92.68M | $87.08M | $81.44M | $77.09M | $73.54M | – | – |
| Oligo pools | – | – | – | $20.23M | $19.84M | $18.58M | $17.81M | $16.91M | $16.04M | $15.60M | $14.98M | $14.49M | – | – |
| DNA libraries | – | – | – | $11.18M | $11.48M | $13.27M | $13.79M | $13.93M | $12.98M | $12.01M | $11.30M | $10.20M | – | – |
By region
| Revenue | TTM Q3 26 | TTM Q2 26 | TTM Q1 26 | TTM Q4 25 | TTM Q3 25 | TTM Q2 25 | TTM Q1 25 | TTM Q4 24 | TTM Q3 24 | TTM Q2 24 | TTM Q1 24 | TTM Q4 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Americas | $257.24M | $239.37M | $230.25M | $225.58M | $220.95M | $212.95M | $203.63M | $193.88M | $184.90M | $172.53M | $161.58M | $151.26M | 59.6% | +16.4% |
| EMEA | $143.89M | $141.01M | $134.30M | $124.24M | $115.19M | $108.03M | $99.65M | $92.57M | $84.27M | $79.76M | $76.28M | $71.39M | 33.3% | +24.9% |
| APAC | $30.67M | $29.10M | $27.00M | $26.75M | $26.13M | $26.70M | $26.90M | $26.52M | $26.04M | $25.20M | $24.51M | $22.46M | 7.1% | +17.4% |
From the segment and revenue-disaggregation notes of Twist Bioscience's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.